Xenetic Biosciences公司扩大与Scripps研究所的研发合作以推进DNase平台的发展Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

动脉网07-24

Xenetic Biosciences, Inc. a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has continued its ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2553249271?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-24 14:33","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2553249271","market":"us","top_or_hot":-1,"title":"Xenetic Biosciences公司扩大与Scripps研究所的研发合作以推进DNase平台的发展Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform","media":"动脉网","content":"<div>\n<p>Xenetic Biosciences, Inc. a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has continued its ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072414341394b7aa72&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xenetic Biosciences公司扩大与Scripps研究所的研发合作以推进DNase平台的发展Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXenetic Biosciences公司扩大与Scripps研究所的研发合作以推进DNase平台的发展Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-24 14:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072414341394b7aa72&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Xenetic Biosciences, Inc. a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has continued its ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072414341394b7aa72&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XBIO","symbol_name":"Xenetic Biosciences Inc","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072414341394b7aa72&s=b","article_id":"2553249271","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072414341394b7aa72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2553249271","pubTimestamp":1753338780,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Xenetic's systemic DNase I candidate, XBIO-015, is currently in preclinical development in combination with CAR-T cell therapy for both hematologic and solid tumors. Studies conducted at TSRI using lymphoma and metastatic melanoma models have shown that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and markedly extends survival compared to CAR-T cell monotherapy.Xenetic的系统性DNase I候选药物XBIO-015目前正在与CAR-T细胞疗法联合进行血液肿瘤和实体瘤的临床前开发。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"XBIO":"Xenetic Biosciences Inc","BK4139":"生物科技","XBIOW":"Xenetic Biosciences, Inc."},"translate_title":"Xenetic Biosciences Expands R&D Collaboration with Scripps Research Institute to Advance DNase Platform Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBIO":0.9,"XBIOW":1},"content_text":"Xenetic Biosciences, Inc. a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has continued its collaboration with The Scripps Research Institute ('TSRI') to advance the development of the Company's development program evaluating the combination of systemic DNase I and CAR T-cell therapies..Xenetic Biosciences, Inc.是一家致力于推进创新免疫肿瘤技术的生物制药公司，专注于治疗难治性肿瘤适应症。该公司今日宣布继续与斯克里普斯研究所（TSRI）合作，以推进其评估系统性DNase I与CAR T细胞疗法联合使用的开发项目。Xenetic's systemic DNase I candidate, XBIO-015, is currently in preclinical development in combination with CAR-T cell therapy for both hematologic and solid tumors. Studies conducted at TSRI using lymphoma and metastatic melanoma models have shown that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and markedly extends survival compared to CAR-T cell monotherapy.Xenetic的系统性DNase I候选药物XBIO-015目前正在与CAR-T细胞疗法联合进行血液肿瘤和实体瘤的临床前开发。在TSRI使用淋巴瘤和转移性黑色素瘤模型开展的研究表明，与单独使用CAR-T细胞疗法相比，DNase I与CAR-T细胞联合使用可显著减少肿瘤负荷、降低转移病灶，并大幅延长生存期。Importantly, systemic DNase I-mediated degrading of neutrophil extracellular traps (NETs) enhances CAR-T cell efficacy increasing the infiltration of both CAR-T cells and endogenous T cells into tumors and by mitigating the immunosuppressive tumor microenvironment (TME). Based on these promising results, the research program has been expanded to include additional models of lymphoma and leukemia to further validate these findings..重要的是，系统性DNase I介导的中性粒细胞胞外陷阱（NETs）降解通过增加CAR-T细胞和内源性T细胞对肿瘤的浸润，并缓解免疫抑制性肿瘤微环境（TME），从而增强了CAR-T细胞的疗效。基于这些有希望的结果，研究计划已扩展到包括淋巴瘤和白血病的其他模型，以进一步验证这些发现。'We are pleased to further expand our collaboration with Scripps Research and explore the full potential of our DNase-based oncology platform. The data generated to date continues to be encouraging and we believe provides a compelling rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR-T cell therapy.“我们很高兴能够进一步扩大与Scripps研究所的合作，充分挖掘我们基于DNase的肿瘤学平台的潜力。迄今为止生成的数据依然令人鼓舞，我们相信这为将DNase I作为辅助治疗手段以改善接受CAR-T细胞疗法患者的治疗反应提供了有力的支持。We are grateful for the Scripps Research team and look forward to continuing to leverage their knowledge and expertise,' commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic..詹姆斯·帕斯洛，Xenetic临时首席执行官兼首席财务官评论道：“我们对斯克里普斯研究团队深表感谢，并期待继续利用他们的知识和专业技能。”Xenetic's DNase-based oncology platform is designed to target NETs, which are weblike structures composed of extracellular chromatin coated with histones and other proteins. In cancer, NETs are expelled by activated neutrophils into the TME and blood, thereby promoting cancer spread and local and systemic immunosuppression.Xenetic的基于DNase的肿瘤学平台旨在靶向NETs，这些网状结构由涂有组蛋白和其他蛋白质的细胞外染色质组成。在癌症中，NETs被活化的中性粒细胞释放到肿瘤微环境（TME）和血液中，从而促进癌症扩散以及局部和全身的免疫抑制。Reduction of NETs burden via application of Xenetic's proprietary recombinant human DNase I has been shown to improve efficacy of immunotherapy, adoptive cell therapy and chemotherapy in preclinical animal models..通过应用Xenetic的专有重组人DNase I来减少NETs负担，已被证明在临床前动物模型中可提高免疫治疗、过继细胞治疗和化疗的疗效。Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors.Xenetic继续推进其基于DNase的技术，用于治疗胰腺癌及其他局部晚期或转移性实体瘤的1期临床开发。About Xenetic Biosciences关于Xenetic生物科学Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers.Xenetic Biosciences, Inc. 是一家生物制药公司，专注于推进针对难以治疗的癌症的创新免疫肿瘤技术。该公司的DNase技术旨在通过靶向中性粒细胞胞外陷阱（NETs）来改善现有治疗方法（包括免疫疗法）的效果，NETs 与许多人类癌症的进展有关。Xenetic is currently focused on advancing its systemic DNase I program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors..Xenetic目前正专注于将其全身性DNase I项目推进到临床，作为胰腺癌和局部晚期或转移性实体瘤的辅助治疗。For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.有关更多信息，请访问公司网站 www.xeneticbio.com，并在 X、LinkedIn 和 Facebook 上进行连接。Forward-Looking Statements前瞻性声明This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws.本新闻稿包含我们希望根据1995年《私人证券诉讼改革法案》的安全港条款进行保护的前瞻性陈述。本新闻稿中除历史事实陈述之外的所有陈述，均可能构成联邦证券法意义上的前瞻性陈述。These statements can be identified by words such as 'expects,' 'plans,' 'projects,' 'will,' 'may,' 'anticipates,' 'believes,' 'should,' 'intends,' 'estimates,' 'remain,' 'focus', 'confidence in', 'potential', 'making', and other words of similar meaning, including, but not limited to: continuing to leverage the knowledge and expertise of the team at Scripps to potentially expand and broaden the utility of our proprietary platform technology; and expectations regarding our DNase-based oncology platform, including statements regarding: advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications; focusing on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications; advancing the development of the Company's program on the combination of systemic DNase and CAR T-cell therapies; our belief that preclinical data that highlights the critical role of NETs in modulating CAR-T cell efficacy provides a compelling rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR-T cell therapy; plans to advance our DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors; the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellul.这些声明可以通过诸如“预期”、“计划”、“预测”、“将”、“可能”、“预计”、“相信”、“应该”、“意图”、“估计”、“保持”、“专注”、“对...的信心”、“潜力”、“进行中”等词语来识别，其他类似含义的词语包括但不限于：继续利用Scripps团队的知识和专业知识，以潜在扩展和拓宽我们专有平台技术的用途；以及关于我们基于DNase的肿瘤学平台的预期，包括以下声明：推动基于DNase的肿瘤学项目进入多项适应症的临床概念验证研究；专注于推进针对难以治疗的肿瘤适应症的创新免疫肿瘤学技术；推动公司系统性DNase与CAR-T细胞疗法联合项目的开发；我们相信，强调NETs在调节CAR-T细胞疗效中的关键作用的临床前数据为将DNase I作为辅助治疗纳入以改善接受CAR-T细胞治疗患者的治疗反应提供了有力的理由；计划将我们的基于DNase的肿瘤学项目推进到1期临床开发阶段，用于治疗胰腺癌及其他局部晚期或转移性实体瘤；通过靶向中性粒细胞胞外诱捕网（NETs），该DNase平台能够改进现有疗法（包括免疫疗法）的效果。Contact:联系人:JTC Team, LLCJTC团队有限责任公司Jenene Thomas珍妮·托马斯(908) 824-0775(908) 824-0775xbio@jtcir.comxbio@jtcir.comSource: xeneticbio.com来源：xeneticbio.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2553249271","isCrawlerRequest":true}